Central anxious system-based cancers have a higher mortality price using the 2016 estimates at 6. that created because of hypoxia. Mainly hypoxia-inducible element-1α vascular endothelial development element (VEGF)/VEGF receptor changing development element-β epidermal development element receptor and PI3 kinase/Akt signaling systems get excited about tumor development and development. Glioblastomas are predominantly hypoxia-induced and glycolytic elements are of help in the metabolic reprogramming of the tumors. Abnormal vessel development is vital in producing pseudopalisading necrosis areas that protect tumor stem cells surviving in that area from therapeutic real estate agents which facilitates the cancer stem cell niche to expand and contribute to cell proliferation and tumor growth. Therapeutic approaches that target hypoxia-induced factors such as use of the monoclonal antibody against VEGF bevacizumab have been useful only in stabilizing the disease but failed to increase overall survival. Hypoxia-activated TH-302 a nitroimidazole prodrug of cytotoxin bromo-isophosphoramide mustard appears to be more attractive due to its better beneficial effects in glioblastoma 3-Methyladenine patients. A better understanding of the hypoxia-mediated protection of 3-Methyladenine glioblastoma cells is required for developing more effective therapeutics. as a glioblastoma. From the stage of glioblastoma occurrence there is a poor survival rate with a median of 16 months and survival rate of approximately 3% (5). It is extremely difficult to eliminate the glioblastoma even with total resection as tumor cells persist microscopically with tumor recurrence occurring in 90% of the patients at the original tumor location (6). The frequently seen extensive hypoxic regions in glioblastomas contribute to the highly malignant phenotype of these tumors exacerbating the prognosis and clinical outcomes of the patients. Hypoxic tumor cells are more resistant to chemo- and radiation therapy (7 8 and are protected by the vasculature that 3-Methyladenine develops due to hypoxia-mediated molecular processes (3). Hypoxia also supports the survival of neural and glioma stem cells which are drug resistant and 3-Methyladenine possess tumorigenicity potential (9 10 Considering the significance of hypoxia in the growth and aggressiveness of glioblastomas targeting hypoxia potentially improves the outcomes in patients with this lethal cancer type. 2 of hypoxia in development of glioblastoma The pathognomonic feature of pseudopalisading necrosis which is the area of hypercellularity surrounding necrotic regions and vascular proliferation observed in glioblastoma tumors is a manifestation of hypoxia. These hypercellularity regions are highly hypoxic and represent tumor cells migrating away from vasoocclusive distorted and degenerating blood vessels from the tumor center. Additionally the cells have a high expression of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) which promote angiogenesis (11). A subset of growth factors including angiopoietins fibroblast growth factors chemokines and matrix metalloproteinases play an important role in tumor angiogenesis (12). These new vessels are deformed leaky and have gaps between endothelial cells resulting in vascular stasis. Repeated cycle of events of angiogenesis vascular collapse due to deformation and cancer cell migration contribute to rapid tumor expansion in adjacent normal tissue and invasion (13). Inasmuch as hypoxia drives the progression and aggressiveness of glioblastoma tumors a strategy for the treatment of this type of cancer has been developed by measuring tumor volume and the extent of intratumoral hypoxia using fluoromisonidazole probe-based positron VPS15 emission tomography followed by appropriate targeting of hypoxic cells to improve the treatment outcome (14). As mentioned above tumor stem cells residing in hypoxic pseudopalisading zones are guarded from chemoradiation because of vascular stasis and depletion of molecular oxygen. In a prospective clinical trial testing bevacizumab and irinotecan in glioblastoma patients it was observed.